Clinical Study of Effects of Targeting Therapy with Iodine-131 Labeled Monoclonal Antibody for Hepatocellular Carcinoma / 中国普外基础与临床杂志
Article
en Zh
| WPRIM
| ID: wpr-546246
Biblioteca responsable:
WPRO
ABSTRACT
Objective To investigate the clinical effects of targeting therapy with iodine-131 labeled monoclonal antibody for hepatocellular carcinoma(HCC).Methods The related published literatures were reviewed and summarized.Results The reasonable application of targeting therapy with iodine-131 labeled monoclonal antibody could improve the prognosis for patients with HCC especially for some primary HCC.It was used in various kinds of HCC patients with no severe side effects.Conclusion The targeting therapy with iodine-131 labeled monoclonal antibody may be considered as a safe and effective method to treat HCC and an adjuvant therapy for liver surgery.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Bases and Clinics in General Surgery
Año:
2003
Tipo del documento:
Article